Offer

We support your projects with customized support, scientific and technical advice and high-value added services throughout the value chain of the development of therapeutic and prophylactic microbiome-based or drug candidates targeting infectious diseases.

Cynbiome® offers an innovative set of solutions to unlock the potential of drugs, vaccines candidates and human microbiome-based products targeting infectious diseases.

A one-stop-shop to support the preclinical development of your pipeline and move faster towards clinic.

Strain Identification (aerobic, anaerobic or GMO strains), targeted isolation

Strain Characterization

● Genotyping, phenotyping
● Resistance and biochemical profiling
● Metagenomic, Whole genome sequencing (WGS)
Sorting & cultivation of microorganisms in controlled atmosphere

Purification, Quality, Optimization

Computational analyses: bioinformatics, statistics, machine learning, AI

Banking system

Working cell banks & Master cell banks

Formulation and delivery systems

● Formulation : Live Biotherapeutic products, Drugs, inhaled products and aerosol therapies
● Fermentation model to select relevant culture media, quality testing by flow cytometry
● Delivery system (including inhaled produtcs)
Galenic preparation for LBPs

Pharmaceutical process development (drug substance, drug product) for LBPs

R&D and preclinical batches

● Aerobic & anaerobic controlled conditions
● Quality testing – flow cytometry or NMR flow cytometry or NMR (viability, purity, bacterial load)
cGMP manufacturing

In silico prediction

Microfluidic organs-on-chips - Microbiota-on-chip

Specific ex vivo models

● Next-generation platforms for phenotypic screening, co-culture systems for human cells and microbes
● Cell lines: Human bronchial epithelial cell lines, Vero 6
Evaluate the pharmacology, toxicity of prophylactic and therapeutic candidates as well as pharmacomicrobiomic and toxicomicrobiomic interactions.

In vitro : Microfluidic, other in vitro models

Ex vivo : 3D models, Microfluidic organs-on-chips

In vivo models (rodent and non-rodent species)

Type of studies frequently performed:
• Exploratory pharmacology: PK/PD profiling
• Early tox studies
• Biodistribution studies (risks associated with Dose selection, dose regimen)
• Immunogenicity studies
• Impact of environmental factors
• Translocation, migration, infection


● Non-rodent (NHP)

The non-human primate model has several advantages for assessing candidates targeting infectious diseases. NHP is a relevant model to derisk leads before moving to the clinics
• Sensitivity to similar pathogens as humans
• Proximity of the immune system
• Close composition of microbiota
Biological readouts

● Functional assays, ELISPOT, FACS, cytokines (MSD, ultrasensitive assays)...
● Human immune repertoire and inflammatory biomarkers
● Microneutralization assays (BSL 2/3)
● Histopathology, immunohistochemistry (for NHP)
Preferential access to characterized human viral strains and other supply sources

In vitro models : human respiratory epithelium model, cell culture (Vero E6)

Ex vivo models : organ on chip, microbiota on chip

In vivo models (rodent and non-rodent species):

● Rodents models: Transgenic, axenic, gnotobiotic mice, Immunocompromised animal models
● Non-human primates: Infectious diseases NHP models (established or on-demand models), Microbiota transplanted NHP models
Biological readouts

● Viral analysis (RT-qPCR, viral titration by TCID50), BSL 2/3
● Microneutralization assays
Microbiomics

“Multi-omics” approach for Microbiome profiling on different type of samples including complex samples (example: feces, …)

● Microbial sequencing (NGS short & long reads): Metagenomics (WGS, 16S, shotgun), single cell
● Metabolomics, Transcriptomics
Flow cytometry for bacteria (aerobic/anaerobic)

Biomolecular & Computational analyses

Imaging (whole body, rodent)

Explore host-microbiota, pharmacomicrobiomic interactions and how the microbiome influence health and disease.

In vitro/ex vivo assays for predictive response on targeted human microbiota

● Organ-on-a-chip
● Next-generation platforms for phenotypic screening, co-culture systems for human cells and microbes
● Human bronchial epithelium, Cell lines (Vero E6)
In vivo models (rodent and non-rodent species):

● Rodents: Transgenic, axenic, gnotobiotic mice, Immunocompromised animal models
● Non-human primates: Infectious diseases NHP models (established or on-demand models), Microbiota transplanted NHP models
Biological readouts

● Functional assays, Immunoassays, Metabolic phenotyping, Molecular biology
● Human immune repertoire and inflammatory biomarkers
● Viral analysis (RT-qPCR, viral titration by TCID50), BSL 2/3
● Microneutralization assays
Microbiomics

“Multi-omics” approach for Microbiome profiling on different type of samples including complex samples (example: feces, …)

● Microbial sequencing (NGS short & long reads)
● Metabolomics, Transcriptomics
Flow cytometry for bacteria (aerobic/anaerobic)

Biomolecular & Computational analyses

Imaging (whole body, rodent)

Towards the clinics: identify translational soluble, cell and microbiome-based clinical biomarkers

Current available biomarkers and discovery of novel biomarkers in different types of samples (blood, urine, faeces, tissues, microbiome biomarkers).

Method development & validation, testing

Highly specialized technological platform for soluble and cell biomarkers

Indirect biomarkers by imaging (MRI)

Microbiomics

“Multi-omics” approach for Microbiome profiling on different type of samples including complex samples (example: feces, …)

● Microbial sequencing (NGS short & long reads): Metagenomics (WGS, 16S, shotgun), single cell
● Metabolomics, Transcriptomics
Flow cytometry of bacteria (aerobic/anaerobic)

Biomolecular & Computational analyses

Big data analytics